Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 4/20 | 0.53 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | CTSK | P43235 | 2/20 | 0.49 |
| ▸ | ELANE | P08246 | 1/20 | 0.48 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18354927 | 1.00 | CTSL (0.53) | CTSLHCAR2ATMCTSKELANE | |
| SCHEMBL18352692 | 0.96 | HCAR2 (0.56) | CTSLHCAR2ATMCTSKELANE | |
| SCHEMBL18353172 | 0.96 | HCAR2 (0.56) | CTSLHCAR2ATMCTSKELANE | |
| SCHEMBL18355332 | 0.91 | CTSL (0.59) | CTSLHCAR2ATMCTSKELANE | |
| SCHEMBL18355240 | 0.91 | CTSL (0.59) | CTSLHCAR2ATMCTSKELANE | |
| SCHEMBL18355123 | 0.90 | HCAR2 (0.50) | CTSLHCAR2ATMCTSKELANE | |
| SCHEMBL18354891 | 0.90 | HCAR2 (0.50) | CTSLHCAR2ATMCTSKELANE | |
| SCHEMBL18354912 | 0.89 | CTSL (0.51) | CTSLHCAR2ATMCTSKELANE | |
| SCHEMBL18354859 | 0.89 | CTSL (0.51) | CTSLHCAR2ATMCTSKELANE | |
| SCHEMBL18355133 | 0.86 | CTRB1 (0.61) | CTSLHCAR2CTSKCTRB1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170001953-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2017-01-05 | — | — | US | disclosed |
| US-20170001953-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2017-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170001953-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, FPGS, APC | CTSL 2900/4885HCAR2 290/4885ATM 4406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.